Plain-English translation of NCT03128879 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether — a medication that works by a different mechanism than or — can be safely combined with these drugs to better control chronic lymphocytic leukemia (CLL), especially in patients whose cancer has high-risk features. Patients in the study will take the medication by mouth daily, along with their current treatment, for up to 24 weeks to see if this combination helps eliminate more cancer cells than the current drugs alone.
Some patients with high-risk CLL continue to have detectable cancer even after taking or for over a year. Researchers are investigating whether adding this medication to the existing treatment can help achieve deeper cancer control and potentially better long-term outcomes.
You likely qualify if…
You likely don't qualify if…
You will take two oral medications by mouth once or twice daily (depending on which medication you are assigned) for up to 24 weeks, continuing alongside your current treatment. Your doctor will monitor your progress with blood tests and bone marrow biopsies to see how well the cancer is responding. After the active treatment period ends, you will have follow-up visits every 6 to 12 months to track your long-term health and cancer status.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States